Federated Hermes’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Federated Hermes’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,298,578	Closed	-$2.42M	–	2248
2023 Q1	$2.42M	Hold	1,298,578	–	–	0.01%	898
2022 Q4	$2.99M	Hold	1,298,578	–	–	0.01%	801
2022 Q3	$4.18M	Hold	1,298,578	–	–	0.01%	709
2022 Q2	$7.14M	Hold	1,298,578	–	–	0.02%	622
2022 Q1	$3.03M	Hold	1,298,578	–	–	0.01%	909
2021 Q4	$7.84M	Sell	1,298,578 -10,000	-0.8%	-$96.2K	0.01%	720
2021 Q3	$18.1M	Buy	1,308,578 +122,689	+10%	+$1.45M	0.03%	495
2021 Q2	$15.4M	Sell	1,185,889 -5,026	-0.4%	-$67.3K	0.03%	541
2021 Q1	$18.3M	Buy	+1,190,915	New	+$28.1M	0.04%	521

Other funds holding GRCL

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes's GRCL Position: Q2 2023 in Review

Federated Hermes sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2023, closing a stake of 1,298,578 shares — an estimated $2.42M sold.

Federated Hermes first reported a position in GRCL in Q1 2021 and held it in 9 quarters. The position peaked at $18.3M in Q1 2021. 36 funds tracked by Wall St. Rank hold GRCL as of Q2 2023.

Federated Hermes reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 1,298,578 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2023, an estimated $2.42M.
Federated Hermes first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 9 quarters.
Federated Hermes's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $18.3M in Q1 2021.
36 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.